Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a sell rating to a hold rating in a research report released on Wednesday.
According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
GWPH has been the subject of a number of other reports. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC- and gave the company a buy rating in a research note on Monday, December 4th. Bank of America dropped their price target on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a buy rating for the company in a research note on Tuesday, November 14th. Goldman Sachs Group restated a neutral rating and issued a $124.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Friday, October 6th. ValuEngine downgraded GW Pharmaceuticals PLC- from a hold rating to a sell rating in a research note on Monday, October 2nd. Finally, BidaskClub upgraded GW Pharmaceuticals PLC- from a hold rating to a buy rating in a research note on Friday, December 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $148.78.
Hedge funds have recently bought and sold shares of the business. IHT Wealth Management LLC boosted its stake in GW Pharmaceuticals PLC- by 18.0% in the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 100 shares during the period. Advisor Group Inc. raised its holdings in shares of GW Pharmaceuticals PLC- by 10.7% during the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 145 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new stake in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth approximately $163,000. Woodmont Investment Counsel LLC purchased a new stake in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth approximately $201,000. Finally, Van Hulzen Asset Management LLC purchased a new stake in shares of GW Pharmaceuticals PLC- during the 3rd quarter worth approximately $205,000. Institutional investors and hedge funds own 74.57% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3127461/gw-pharmaceuticals-plc-gwph-upgraded-by-zacks-investment-research-to-hold.html.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.